Literature DB >> 18472925

Tumour Necrosis Factor-alpha Production and Immune Cell Activation in Tuberculous Meningitis.

C M Mastroianni1, F Paoletti, C Valenti, A P Massetti, V Vullo, S Delia.   

Abstract

The local production of tumour necrosis factor-alpha (TNFalpha) was evaluated in the cerebrospinal fluid (CSF) from ten patients with tuberculous meningitis (TBM). The degree of intrathecal immune activation was also studied by assessing the CSF levels of beta(2)-microglobulin (beta(2)-M) and adenosine deaminase activity (ADA). Results indicate that elevated CSF concentrations of TNFalpha, beta(2)-M and ADA were found in all TBM patients. Moreover, TNFalpha is produced and selectively concentrated for a long period of time, while beta(2)-M and ADA values progressively decline during the course of TBM. Our findings suggest that in TBM patients, after an early activation of immune cells, there is an enhanced and continuous production of TNFalpha at the site of infection.

Entities:  

Year:  1994        PMID: 18472925      PMCID: PMC2367021          DOI: 10.1155/S0962935194000104

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  14 in total

1.  T lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection. Evidence for different kinetics and recognition of a wide spectrum of protein antigens.

Authors:  I M Orme; E S Miller; A D Roberts; S K Furney; J P Griffin; K M Dobos; D Chi; B Rivoire; P J Brennan
Journal:  J Immunol       Date:  1992-01-01       Impact factor: 5.422

2.  Activity of adenosine deaminase in cerebrospinal fluid for the diagnosis and follow-up of tuberculous meningitis in adults.

Authors:  E Ribera; J M Martinez-Vazquez; I Ocaña; R M Segura; C Pascual
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

Review 3.  Immunologic aspects of mycobacterial infections.

Authors:  J J Ellner; R S Wallis
Journal:  Rev Infect Dis       Date:  1989 Mar-Apr

4.  Evidence that tumor necrosis factor has an important role in antibacterial resistance.

Authors:  E A Havell
Journal:  J Immunol       Date:  1989-11-01       Impact factor: 5.422

5.  Adenosine deaminase levels in cerebrospinal fluid in the diagnosis of tuberculous meningitis.

Authors:  C Malan; P R Donald; M Golden; J J Taljaard
Journal:  J Trop Med Hyg       Date:  1984-02

6.  Tumor necrosis factor-alpha (TNF alpha) in cerebrospinal fluid from patients with meningitis of different etiologies: high levels of TNF alpha indicate bacterial meningitis.

Authors:  M Glimåker; P Kragsbjerg; M Forsgren; P Olcén
Journal:  J Infect Dis       Date:  1993-04       Impact factor: 5.226

Review 7.  Beta-2-microglobulin levels in the cerebrospinal fluid: their value as a disease marker. A review of the recent literature.

Authors:  N Adachi
Journal:  Eur Neurol       Date:  1991       Impact factor: 1.710

8.  Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta 2-microglobulin in HIV-1-associated tuberculosis.

Authors:  R S Wallis; M Vjecha; M Amir-Tahmasseb; A Okwera; F Byekwaso; S Nyole; S Kabengera; R D Mugerwa; J J Ellner
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

9.  T-cell-mediated protection of mice against virulent Mycobacterium tuberculosis.

Authors:  C Leveton; S Barnass; B Champion; S Lucas; B De Souza; M Nicol; D Banerjee; G Rook
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

10.  Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex.

Authors:  L E Bermudez; L S Young
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

View more
  1 in total

1.  Chemokine profiles in the cerebrospinal fluid (CSF) during the course of pyogenic and tuberculous meningitis.

Authors:  C M Mastroianni; L Lancella; F Mengoni; M Lichtner; P Santopadre; C D'Agostino; F Ticca; V Vullo
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.